Modulation of Short-Term Delivery of Proteins from Hydrogels
Source abstract
Abstract
For modulation of cellular behavior, systems that can provide controlled delivery of proteins (soluble signals) over a few hours to a few days are highly desirable. Conventional erosion-controlled systems are inadequate as their degradation spans days to months. Conversely, hydrogels offer quicker release but are limited by a high burst release that can lead to cytotoxicity and rapid depletion of the permeant. To avoid burst release and achieve controlled diffusion of proteins, we propose exploiting electrostatic interactions between the hydrogel matrix and proteins. Here we demonstrate this concept using two disparate hydrogel systems: (1) a chemically cross-linked protein (gelatin) matrix and (2) a physically cross-linked polysaccharide (agarose) matrix and three proteins having different isoelectric points. By introducing fixed charges into the hydrogel matrix using carboxylated agarose (CA), the precise and controlled release of BSA, lactoferrin, and FGF2 over a few hours to days is demonstrated. Using electroendosmosis, we further provide evidence for a clear role for CA in modulating the release. Our findings suggest that the paradigm presented herein has the potential to significantly enhance the design of hydrogel systems for the delivery of proteins and RNA therapeutics for vaccines and biomedical applications ranging from tissue engineering to functional coatings for medical devices.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Microfluidic and Bio-sensing Technologies · 3D Printing in Biomedical Research · Pancreatic function and diabetes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute for Macromolecular Chemistry, Hermann-Staudinger-Haus, University of Freiburg, Stefan-Meier-Str. 31, 79104 Freiburg, Germany
BIOSS Centre for Signalling Studies, University of Freiburg, Schänzlestraße 18, 79104 Freiburg, Germany
Funding
Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung · Deutsche Forschungsgemeinschaft
References (47)
Show source-provided references
1. 10.1038/263797a010.1038/263797a0 ↗
2. 10.2174/138920103348969410.2174/1389201033489694 ↗
3. 10.1248/cpb.36.109510.1248/cpb.36.1095 ↗
4. Lamprecht A. · J. Pharmacol Exp Ther · 2001 · 299 · 775
5. 10.1016/S0939-6411(03)00095-X10.1016/S0939-6411(03)00095-X ↗
6. 10.1016/0010-7824(82)90033-610.1016/0010-7824(82)90033-6 ↗
7. 10.1016/S0010-7824(01)00285-210.1016/S0010-7824(01)00285-2 ↗
8. 10.1002/adbi.20180023710.1002/adbi.201800237 ↗
9. 10.1002/jmor.105088010410.1002/jmor.1050880104 ↗
10. 10.1038/185117a010.1038/185117a0 ↗
11. 10.1002/bit.2236110.1002/bit.22361 ↗
12. 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M ↗
13. 10.1111/j.1432-1033.1996.0295n.x10.1111/j.1432-1033.1996.0295n.x ↗
14. 10.1002/jcp.104152022610.1002/jcp.1041520226 ↗
15. 10.1074/jbc.272.29.1800010.1074/jbc.272.29.18000 ↗
16. 10.1160/TH07-04-031010.1160/TH07-04-0310 ↗
17. 10.1083/jcb.144.5.106910.1083/jcb.144.5.1069 ↗
18. 10.1021/acs.biomac.0c0140610.1021/acs.biomac.0c01406 ↗
19. 10.1073/pnas.122288011010.1073/pnas.1222880110 ↗
20. 10.1016/j.jconrel.2005.09.02310.1016/j.jconrel.2005.09.023 ↗
21. 10.1371/journal.pone.017509510.1371/journal.pone.0175095 ↗
22. Dublecco’s PBS. https://www.thermofisher.com/order/catalog/product/de/en/14190094 (accessed October 17, 2024).
23. 10.1002/jcp.104128031710.1002/jcp.1041280317 ↗
24. 10.1038/7191610.1038/71916 ↗
25. Shah M. M. · 2022
26. 10.1038/nmeth.201910.1038/nmeth.2019 ↗
27. 10.1039/cs992210012710.1039/cs9922100127 ↗
28. Smith B. J. · 1984 · 4110.1385/0-89603-062-8:41 ↗
29. 10.1016/S1357-2725(99)00123-510.1016/S1357-2725(99)00123-5 ↗
30. 10.3390/pharmaceutics1206050810.3390/pharmaceutics12060508 ↗
31. DuoSet enzyme-linked immunosorbent assay (ELISA) kit for FGF2 (#DY233) R&D Systems. https://www.rndsystems.com/products/human-fgf-basic-fgf2-bfgf-duoset-elisa_dy233 (accessed August 24, 2024).
32. Thoraflex Hybrid. https://www.fda.gov/medical-devices/recently-approved-devices/thoraflex-hybrid-p210006 (accessed August 24, 2024).
33. GelFoam. https://www.accessdata.fda.gov/SCRIPTS/cdrh/devicesatfda/index.cfm?db=pma&id=347805 (accessed August 22, 2024).
34. 10.1007/s40123-019-0192-810.1007/s40123-019-0192-8 ↗
35. PerioChip. https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774.cfm (accessed August 22, 2024).
36. 10.1016/j.pnmrs.2019.11.00210.1016/j.pnmrs.2019.11.002 ↗
37. 10.1021/ma301666x10.1021/ma301666x ↗
38. 10.1016/j.conbuildmat.2023.13382810.1016/j.conbuildmat.2023.133828 ↗
39. 10.1021/jp409936v10.1021/jp409936v ↗
40. 10.1016/S0021-9258(18)75771-210.1016/S0021-9258(18)75771-2 ↗
41. 10.1016/0014-5793(75)80242-010.1016/0014-5793(75)80242-0 ↗
42. 10.1021/mp400474910.1021/mp4004749 ↗
43. 10.1016/j.jasms.2004.05.00410.1016/j.jasms.2004.05.004 ↗
44. 10.1002/adma.20180805010.1002/adma.201808050 ↗
45. 10.1002/adhm.20220255010.1002/adhm.202202550 ↗
46. 10.1016/j.msec.2019.01.08010.1016/j.msec.2019.01.080 ↗
47. 10.1002/adhm.20170025510.1002/adhm.201700255 ↗